Corcept Therapeutics Incorporated

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 22, 2026, Sean Maduck, the President of Corcept Endocrinology, notified the Board of Directors of Corcept Therapeutics Incorporated (the “Company”) of his decision to resign effective as of October 1, 2026. The Company thanks Mr. Maduck for his significant contributions to the Company and his dedication to helping patients. Mr. Maduck did not resign because of any disagreement with the Company on any matter relating to the Company’s operations, financial statements, policies or practices. In connection with Mr. Maduck’s resignation, the Company and Mr. Maduck entered into a Consulting Services Agreement (the “Agreement”), dated as of September 22, 2026 and effective as of October 1, 2026, pursuant to which Mr. Maduck will provide consulting services to the Company’s Chief Executive Officer and executive management team. The Agreement has an initial term expiring on September 30, 2027, unless earlier terminated. Pursuant to the Agreement, Mr. Maduck will be paid a cash fee of $57,000 per month. The Agreement further provides that during Mr. Maduck’s consulting term with the Company, Mr. Maduck’s previously awarded and currently outstanding stock options shall continue to vest according to the original vesting schedule of each such stock option. Either party may terminate the Agreement upon thirty (30) days’ prior written notice. The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which will be filed either as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2026 or by amendment to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure. On September 23, 2026, the Company issued a press release announcing the retirement of Mr. Maduck and that Justin Gunn will succeed Mr. Maduck. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 7.01 and the information contained in the press release attached as Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01 and the information contained in the press release attached as Exhibit 99.1 is not incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in the filing unless specifically stated so therein.